Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRESA: Predicting Etanercept Response in Spondyloarthritis
NCT03033095Completed
- Sponsor
- CHU Grenoble Alpes
- Start
- Jul 2016
- Primary completion
- Jul 2017
- Countries
- 1
01
Overview
Open-label, single-arm trial of etanercept in ankylosing spondylitis (AS), sponsored by CHU Grenoble Alpes. Primary endpoint: Ankylosing Spondylitis Disease Activity Score at 6 months. Started Jul 2016; status: completed.
02
Drugs
etanercept
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on NCT03033095.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03033095.